The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated safety and efficacy results from phase I/II study of HM61713 in patients (pts) with EGFR mutation positive non-small cell lung cancer (NSCLC) who failed previous EGFR-tyrosine kinase inhibitor (TKI).
 
Keunchil Park
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; AVEO; Boehringer Ingelheim; Clovis Oncology; Hanmi; Kyowa Hakko Kirin; Lilly; Novartis; Ono Pharmaceutical; Roche Pharma AG
 
Jong-Seok Lee
No Relationships to Disclose
 
Ki Hyeong Lee
No Relationships to Disclose
 
Joo-Hang Kim
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly; Roche Pharma AG
Research Funding - AstraZeneca; Clovis Oncology; Hanmi; Lilly; Roche Pharma AG
 
Young Joo Min
No Relationships to Disclose
 
Jae Yong Cho
No Relationships to Disclose
 
Ji-Youn Han
Honoraria - Novartis
Consulting or Advisory Role - Boehringer Ingelheim
Speakers' Bureau - Pfizer
Research Funding - AstraZeneca; Boehringer Ingelheim; Roche
 
Bong-Seog Kim
No Relationships to Disclose
 
Jin-Soo Kim
No Relationships to Disclose
 
Dae Ho Lee
No Relationships to Disclose
 
Jin Hyoung Kang
No Relationships to Disclose
 
Eun Kyung Cho
No Relationships to Disclose
 
In-Jin Jang
No Relationships to Disclose
 
Jina Jung
Employment - Hanmi
 
Hyo-Yeon Kim
Employment - Hanmi
 
Hui Jung Sin
Employment - AstraZeneca; Hanmi
 
Jeewoong Son
Employment - Hanmi
 
Jong Soo Woo
Employment - Hanmi
 
Dong-Wan Kim
Consulting or Advisory Role - Novartis